American College of Cardiology's Annual Scientific Session & Expo 2022 (ACC.22)

Post-TAVR SLT does not differ with edoxaban or DAPT

Post-TAVR SLT risk does not differ with edoxaban or DAPT

Roshini Claire Anthony, 20220516160001

The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.

New HF guideline: Quad therapy, HFmrEF, and more

Elvira Manzano, 20220504000000

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

Exercise confers greater benefits in anxiety, depression

Elvira Manzano, 20220430000000

The cardioprotective effects of exercise are nearly twice as large in people with anxiety and depression than in those without, suggests a new study presented at ACC.22.

Adjunctive mavacamten averts need for invasive therapy in OHCM

Elvira Manzano, 20220428000000

Adding mavacamten – an allosteric modulator of cardiac myosin – to maximal medical therapy slashes the need for septal reduction therapy (SRT) in patients with obstructive hypertrophic cardiomyopathy (OHCM) who are candidates for such intervention, the VALOR-HCM trial has shown.

Annual flu jab in HF patients may lower hospitalization, pneumonia risk

Roshini Claire Anthony, 20220427180001

An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.

Novel drug helps optimize HFrEF therapy

Audrey Abella, 20220427100000

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

Inflammation strong predictor of recurrent CV events in CKD

Elvira Manzano, 20220426000000

Residual inflammation is a strong predictor of recurrent cardiovascular (CV) events than hyperlipidaemia in patients with atherosclerotic disease and impaired kidney function in a sub-study of the CANTOS* trial.

Renal denervation aids in long-term blood pressure control

Tristan Manalac, 20220425090000

Patients with uncontrolled hypertension can benefit from renal sympathetic denervation, which leads to notable reductions in systolic blood pressure (SBP) after 6 months of intervention, reports the proof-of-concept SPYRAL HTN-ON MED trial presented at ACC.22.

CHAP backs BP control during pregnancy, even for mild hypertension

Pearl Toh, 20220423150100

Actively treating even mild hypertension to a target blood pressure (BP) of <140/90 mm Hg in pregnant women significantly lowers the risk of adverse pregnancy outcomes without apparent harm to the foetus compared with a strategy of reserving treatment to only when hypertension becomes severe (≥160/105 mm Hg), according to the CHAP* study presented at ACC 2022.

Finerenone reduces CV events, renal outcomes in T2D-related CKD

Stephen Padilla, 20220422120000

A pooled analysis of 13,171 patients from both the FIDELIO-DKD and FIGARO-DKD trials has confirmed the beneficial effects of finerenone, according to results of FIDELITY study, presented at the recently concluded American College of Cardiology Annual Scientific Session (ACC 2022).